Commercial Fishing Safety

Business

Trump Threatens 50% Tariff, Decertification of Canadian Aircraft in Escalating Trade Dispute

In a late-night social media post, former President Donald Trump threatened to impose a 50% tariff on all Canadian aircraft sold in the U.S. and decertify new planes, citing Canada's alleged refusal to certify Gulfstream jets. The move, targeting Bombardier, risks disrupting U.S. regional aviation and corporate travel.

Jan 30, 2026

World

UK-China Relations Thaw as Starmer Seeks Economic Reset Amid Global Trade Shifts

Prime Minister Keir Starmer's landmark visit to Beijing marks a cautious pivot in UK-China relations, yielding agreements on tariffs, visas, and green energy. But can British businesses navigate the opportunities and challenges of re-engagement?

Jan 30, 2026

Business

Valero Energy Caps Record Year with Soaring Q4 Profits, Eyes Policy Shifts and Venezuelan Crude

Valero Energy reported a robust fourth quarter, with net income surging to $1.1 billion, driven by strong refining margins and record operational performance. While renewable diesel faced headwinds, ethanol profits soared. The company outlined disciplined capital plans and highlighted potential tailwinds from policy clarity and increased access to discounted heavy crude.

Jan 30, 2026

Business

Microsoft's AI Bet Pays Off: Q2 Profits Soar 60% to $38.5 Billion as Cloud Demand Accelerates

Microsoft's second-quarter earnings smashed expectations, fueled by a 26% surge in cloud revenue that crossed the $50 billion mark for the first time. The tech giant's aggressive AI investments are now driving significant growth across its enterprise stack.

Jan 30, 2026

Business

Armstrong World Industries: A Buying Opportunity After Recent Dip, or Overvalued Despite Pullback?

Shares of the building products manufacturer have retreated from recent highs, presenting investors with a valuation puzzle. While a key cash flow model suggests the stock is undervalued, its premium P/E ratio tells a more cautious story. We break down the conflicting signals.

Jan 30, 2026

Business

Bitcoin's Luster Fades Against Gold, Revisiting 2017 Ratio as Debate Over Digital Haven Intensifies

The Bitcoin-to-gold ratio has slumped close to its 2017 level, fueling a fresh round of scrutiny over the cryptocurrency's viability as a long-term store of value amidst a resurgent precious metals market and persistent macroeconomic uncertainty.

Jan 30, 2026

Business

Visa Posts Strong Q1 Results as Consumer Spending Holds Steady, Digital Services Fuel Growth

Visa's fiscal first-quarter earnings surpassed expectations, driven by robust cross-border transactions and a surge in high-margin digital services. The payments giant signals confidence in sustained consumer resilience despite some moderation in U.S. debit volumes.

Jan 30, 2026

Business

United Rentals Caps Record 2025, Eyes Another Year of Growth Fueled by Mega-Projects

United Rentals reported strong Q4 results, driven by data center and power sector demand, and issued 2026 guidance forecasting continued revenue growth. Management highlighted a robust project pipeline while navigating margin pressures.

Jan 30, 2026

Business

Thermo Fisher Scientific Caps 'Strong Year' with Robust Q4, Eyes Strategic Growth Amid Market Headwinds

Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.

Jan 30, 2026

Business

SL Green Executives Bullish on NYC Office Rebound, Detail $9.5B Capital Strategy

In its Q4 2025 earnings call, SL Green Realty projected strong fundamentals for Manhattan's office market, citing robust leasing and AI-driven demand. Management reiterated ambitious 2026 financing and asset sale targets while reporting quarterly results that beat expectations.

Jan 30, 2026

Business

Southside Bancshares Navigates Higher Rates, Posts Q4 Profit Rebound Amid Strategic Portfolio Shift

Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.

Jan 30, 2026

Business

BofA Doubles Down on Hesai Group, Boosts Price Target on Lidar Leadership and Regulatory Tailwinds

Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.

Jan 30, 2026

Business

UBS Initiates Coverage on Zai Lab with Buy Rating, Touts Global Ambitions Beyond China

Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.

Jan 30, 2026

Business

Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith

H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.

Jan 30, 2026

Business

Analysts Bullish on BeOne Medicines: Phase 3 Success Fuels $3.8B Revenue Forecast for 2025

Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.

Jan 30, 2026

Business

RBC Lifts Price Target on Ascendis Pharma, Backs Growth Trajectory Through 2026

RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.

Jan 30, 2026

Business

Argenx's Vyvgart Surges Past Sales Forecasts, Fueling Optimism for Autoimmune Portfolio

Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.

Jan 30, 2026

Business

Bargain Hunt: UK Stocks Trading at Steep Discounts Amid Market Jitters

As the FTSE indices reel from weak Chinese trade data, a screen of undervalued UK equities reveals potential opportunities. We examine three companies trading significantly below their estimated cash flow value.

Jan 30, 2026

World

France Blocks Eutelsat's Ground Antenna Sale, Citing Strategic Sovereignty Concerns

The French government has intervened to stop satellite operator Eutelsat from selling its ground antenna assets, framing the move as a defense of European strategic autonomy against rivals like SpaceX's Starlink.

Jan 30, 2026

Business

ResMed Posts Strong Q2 Growth, Eyes GLP-1 Tailwind and AI-Driven Innovation

ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.

Jan 30, 2026